RCAR RenovaCare Inc

RenovaCare Elects Alan L. Rubino to Chairman of the Board of Directors

RenovaCare Elects Alan L. Rubino to Chairman of the Board of Directors
EN
05/10/2020

Underlying

RCARRenovaCare Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RenovaCare Inc

 PRESS RELEASE
Free
RCAR RENOVACARE INC

RenovaCare Announces Termination of StemCell Systems R&D Agreement

RenovaCare Announces Termination of StemCell Systems R&D Agreement SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; ), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced the termination of its July 1, 2020 Strategic Research and Development Agreement with StemCell Systems GmbH (SCS) and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany. This decision ceases on-going development of the prototype for the closed, automated Cell I...

May 3, 2022 1 EN
 PRESS RELEASE
Free
RCAR RENOVACARE INC

RenovaCare Announces Management Changes

RenovaCare Announces Management Changes SCOTTSDALE, Ariz., March 24, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; ), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced reductions in its management team to further streamline administrative expenses. On March 24, Dr. Kaiyo Nedd resigned as Interim President, Chief Executive Officer and Director, and Mr. Justin Frere as Chief Financial Officer and Secretary. Their resignations were not due to any disagreements between the...

March 24, 2022 1 EN
 PRESS RELEASE
Free
RCAR RENOVACARE INC

RenovaCare Provides Clinical and Corporate Update

RenovaCare Provides Clinical and Corporate Update SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; ), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs. These actions are due to a variety of factors, including (i) COVID-19 related low patient...

March 9, 2022 1 EN
 PRESS RELEASE
Free
RCAR RENOVACARE INC

RenovaCare Establishes Leadership Position in Cell Isolation and Spray...

RenovaCare Establishes Leadership Position in Cell Isolation and Spray Technology with Newly Awarded U.S. Patent SCOTTSDALE, Ariz., Oct. 14, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; ), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the award of a new SkinGun™ patent by the United States Patent and Trademark Office (US Patent No. 11,135,380). The latest RenovaCare patent demonstrates the Company’s commitment to developing new products and expanding its proprietary cell isolation and spray technology platforms to now...

October 14, 2021 1 EN
 PRESS RELEASE
Free
RCAR RENOVACARE INC

RenovaCare Provides Update on Clinical Trial for the SkinGun™ and Cell...

RenovaCare Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing ROSELAND, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; ), developer of patented technologies for the regeneration of skin and other organs and tissues, today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient. Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center. T...

July 22, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch